---
layout: default
title: Apis Mellifera Arctostaphylos Uva-Ursi Leaf Arseni
parent: 僅模型預測 (L5)
nav_order: 384
evidence_level: L5
indication_count: 0
---

# Apis Mellifera Arctostaphylos Uva-Ursi Leaf Arseni
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Component Herbal/Homeopathic Complex: Insufficient Data for Repurposing Assessment

## One-Sentence Summary

This candidate is a seven-ingredient complex containing APIS MELLIFERA, ARCTOSTAPHYLOS UVA-URSI LEAF, ARSENIC TRIOXIDE, CALCIUM SULFIDE, LYTTA VESICATORIA, SMILAX ORNATA ROOT, and SOLIDAGO VIRGAUREA FLOWERING TOP — a profile consistent with a homeopathic or naturopathic combination product.
The TxGNN model returned **no predicted new indications** for this multi-ingredient entry, which most likely occurs because the pipeline could not resolve the composite INN to a single DrugBank node.
Without a prediction target, a standard repurposing evaluation cannot be completed at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | None on record (not registered in the US) |
| Predicted New Indication | No TxGNN prediction available |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — model prediction only (currently no prediction generated) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why Is No Prediction Available?

The TxGNN knowledge graph operates on individual DrugBank-mapped entities. This submission lists seven distinct botanical, mineral, and zoological ingredients as a single INN string, separated by semicolons. Because the pipeline could not resolve the composite string to a single DrugBank ID (`drugbank_id: null`), the graph traversal had no valid starting node and returned an empty prediction set.

Each component, taken individually, carries its own pharmacological profile:

- **Arsenic Trioxide** — a well-characterised antineoplastic agent approved for acute promyelocytic leukaemia (APL); its mechanism involves degradation of the PML-RARα fusion protein and induction of apoptosis in leukaemic cells.
- **Arctostaphylos Uva-Ursi Leaf** — contains arbutin, a urinary antiseptic with documented use in lower urinary tract infections.
- **Solidago Virgaurea** — traditionally used as a diuretic and for urinary tract inflammation; supported by European monographs (EMA/HMPC).
- **Lytta Vesicatoria** — source of cantharidin; historically applied in homeopathy for genitourinary complaints.
- **Apis Mellifera, Calcium Sulfide, Smilax Ornata Root** — used in homeopathic preparations; limited evidence base in conventional pharmacology.

The combination profile (heavy urinary-tract ingredients + one potent cytotoxic component) does not map cleanly to a single disease target, which further explains the absent prediction.

---

## Cytotoxicity Note

> **Note**: Arsenic trioxide is one of the seven listed components. Because it is a recognised antineoplastic agent, the following cytotoxicity considerations apply if arsenic trioxide constitutes a therapeutically active portion of this formulation.

| Item | Content |
|------|---------|
| Cytotoxicity Classification | Conventional cytotoxic — heavy metal / pro-apoptotic agent (arsenic trioxide component) |
| Myelosuppression Risk | Please refer to arsenic trioxide package insert; leucocytosis and differentiation syndrome are known risks in APL treatment |
| Emetogenicity Classification | Low to moderate (arsenic trioxide monotherapy class) |
| Monitoring Items | ECG (QTc prolongation), CBC with differential, liver and renal function, serum electrolytes (K⁺, Mg²⁺) |
| Handling Protection | If arsenic trioxide is a quantifiable active ingredient, cytotoxic drug handling regulations apply |

---

## Safety Considerations

Please refer to the individual component package inserts and the prescribing information for arsenic trioxide for safety information. No combined-product safety data, DDI records, or registered warnings were found for this multi-ingredient entry.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline could not generate a repurposing prediction because the composite INN could not be resolved to a DrugBank node; without a prediction target, repurposing evaluation is blocked at the entry point. Additionally, the product has zero US regulatory authorisations and no safety profile on record.

**To proceed, the following is needed:**

- **Decompose the query**: Submit each of the seven ingredients as separate TxGNN queries (e.g., Arsenic Trioxide → DrugBank DB01169) and aggregate individual predictions.
- **Identify the intended formulation**: Confirm whether this is a homeopathic, naturopathic, or combination prescription product, and obtain the corresponding product monograph or package insert.
- **Resolve MOA data gap (DG002)**: Query DrugBank for each active ingredient individually to obtain mechanism-of-action data.
- **Obtain safety data (DG001)**: Retrieve package insert warnings and contraindications for arsenic trioxide specifically, as it carries a black-box warning (APL differentiation syndrome, QTc prolongation, hepatotoxicity).
- **Clarify regulatory status**: Determine if this product is registered in any jurisdiction under a homeopathic or traditional medicine pathway, which would provide an original indication for anchoring repurposing analysis.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

